Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis with Its Novel Bispecific Antibody ATI-052
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4R? Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology Congress
Alrajhi Medicine to Digitize its Healthcare Operations with Oracle to Foster Better Patient and Staff Experiences
Zscaler 2026 AI Threat Report: 91% Year-over-Year Surge in AI Activity Creates Growing Oversight Gap for Global Enterprises
Vizsla Copper Receives Letter of Support from Alaska Governor and Outlines 2026 Exploration Plans at the Palmer Project
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
